Exact Sciences Partners With West German Study Group to Validate MRD Test in Breast Cancer
The ADAPT Triad analysis will use data from three ongoing studies to validate the test's ability to inform treatment strategy and monitor recurrence.
Stay updated with breaking news from German Study Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The ADAPT Triad analysis will use data from three ongoing studies to validate the test's ability to inform treatment strategy and monitor recurrence.
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, announced today that it has entered a collaboration agreement with...
This oncologic clinical trial evaluates the efficacy and safety of the CDK 4/6 Inhibitor Abemaciclib in combination with endocrine therapy in high-risk early breast cancer patients Cologne, Germany, 07.01.2021 – CANKADO, the leading digital health application developers in Germany, assists the recently started clinical trial, ADAPTlate, organized by West German Study Group (WSG) to collect the Patient Reported Outcomes (PROs) by the CANKADO ePRO tool. The clinical trial already enrolled the first patients who are using the CANKADO e-Health system as part of the study to monitor their Qual...
Following is a transcript of their remarks: Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year's San Antonio Breast Cancer meeting. I'm Hope Rugo, professor of medicine at the University of California San Francisco's Comprehensive Cancer Center, and I'm joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco's Comprehensive Cancer Center. Thanks for joining me...
The tool developed on the basis of the ADAPT study data will be presented today at SABCS 2020 Cologne, Germany, 11.12.2020 – The EnReP (Endocrine Response Predictor) assessment tool will be presented today at the San Antonio Breast Cancer Symposium SABCS 2020. EnReP is a tool developed in Germany that can be used to predict the probability of response to endocrine therapy in early-stage breast cancer patients. Endocrine therapy is the standard therapy for hormone receptor-positive (HR+) / HER2-negative (HER2-) breast cancer patients. The ADAPT study program evaluates options for patient-spe...